OncoMatch/Clinical Trials/NCT07215949
Zilucoplan for Severe gMG Exacerbations
Is NCT07215949 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Zilucoplan® for generalized myasthenia gravis (gmg).
Treatment: Zilucoplan® — This is an open-label, multicenter, interventional phase 3b study in participants with AChR+ gMG and severe exacerbation that require hospitalization. Patients will receive subcutaneous zilucoplan injections daily for 12 weeks. Participation in the study will last for approximately 18 weeks.
Check if I qualifyExtracted eligibility criteria
Disease stage
Required: Stage MGFA CLASS II, MGFA CLASS III, MGFA CLASS IVA, MGFA CLASS IVB (MGFA)
MGFA class II - IVb
Prior therapy
Cannot have received: C5 inhibitor
Current use or known failure of C5 inhibitors in the previous 3 months
Cannot have received: plasma exchange
Exception: initiation in the past 4 weeks
Initiation of plasma exchange ... in the past 4 weeks
Cannot have received: IVIG
Exception: initiation in the past 4 weeks
Initiation of ... IVIG in the past 4 weeks
Cannot have received: anti-CD20 antibody (rituximab)
Rituximab use in the previous 9 months
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The Ohio State University · Columbus, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify